Role of microRNAs and pharmacological, pharmacokinetic and pharmacogenetic influences in bortezomib-induced peripheral neuropathy

Role of microRNAs and pharmacological, pharmacokinetic and pharmacogenetic influences in bortezomib-induced peripheral neuropathy - Resolve Pain MiPharm-BIPN

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00025422

Enrollment

120

Registered

2021-05-27

Start date

2021-06-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C90.0 G62.0

Interventions

Group 1: Newly diagnosed patients who have just begun the treatment with bortezomib: multimodal investigation Group 2: Patients in actual treatment with bortezomib

with and without existing peripheral neuropathy: multimodal investigation Group 3: Patients with completed treatment with bortezomib

with and without existing peripheral neuropathy: multimodal investigation

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Multiple Myeloma diagnosed according to current IMWG criteria.

Exclusion criteria

Exclusion criteria: Serious other medical condition that would prevent subject from study participation

Design outcomes

Primary

Measure	Time frame
microRNA 223 Expression via RT-PCR	—

Secondary

Measure	Time frame
Expression of PKNOX1	—

Countries

Germany

Contacts

Public ContactClaudia Sommer

Universitätsklinikum Würzburg Neurologische Klinik

claudia.sommer@uni-wuerzburg.de0931/2010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 10, 2026